ReviewNature reviews. Drug discovery2012
Reducing safety-related drug attrition: the use of in vitro pharmacological profiling.
Review in Nature reviews. Drug discovery, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 301 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
301 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Knowledge-Driven Approaches to Create the MTox700+ Metabolite Panel for Predicting Toxicity.Toxicological sciences : an official journal of the Society of Toxicology · 2022Pooled it
- Large scale meta-analysis of preclinical toxicity data for target characterisation and hypotheses generation.PloS one · 2021Pooled it
- Clinical pharmacology and tolerability of REC-994, a redox-cycling nitroxide compound, in randomized phase 1 dose-finding studies.Pharmacology research & perspectives · 2024Trial
- CUE: A Chemical Uncertainty-Aware Embedding Framework for Multimodal Drug Selectivity Prediction.Journal of chemical information and modeling · 2026Article
- TechBio 3.0 closes the drug discovery loop with multimodal AI and generative chemistry.npj drug discovery · 2026Review
- From Chemical Scaffold to Predicted Toxicity: A Scaffold-Aware Pipeline for Reliable In Silico Prioritization ofInternational journal of molecular sciences · 2026Article
- Small-molecule RAS/RAF inhibitors target RAS-driven cancers via allosteric RAF disruption.Nature communications · 2026Article
- Target-biology and interactome-derived signatures predict target-level associations with safety-related drug attrition.Scientific reports · 2026Article
- Lipophilic Ligand Efficiency-Monitored Discovery of Potent, Achiral, and Bioavailable Apo-IDO1 Inhibitors.ACS medicinal chemistry letters · 2026Article
- ActivityDiff: a diffusion model with positive and negative activity guidance for de novo drug design.Bioinformatics (Oxford, England) · 2026Article
- Building structure activity relationships to avoid toxicity due to unwanted central nervous system ion channel activity.Toxicological sciences : an official journal of the Society of Toxicology · 2026Article
- Toward a Therapy for Autism Spectrum Disorder: The Formyl Peptide Receptor 2 Agonist MR-39 Supports Synaptic Health in the BTBR Mouse and Features a Favorable Safety Profile.ACS pharmacology & translational science · 2026Article
- Discovery ofJournal of medicinal chemistry · 2026Article
- Ligand-agnostic off-target site prediction for early toxicity screening by leveraging point cloud-based protein cavity analysis.Briefings in bioinformatics · 2026Article
- Unveiling the bioactive landscape of drug inactive ingredients (DIGs) using deep transfer learning.Acta pharmaceutica Sinica. B · 2026Article
- Darizmetinib (HRX215): A Promising 1st-in-Class Liver Regenerating Drug in Phase 1b/2a Clinical Development, Targeting the Stress Signaling Protein Kinase MKK4.Journal of medicinal chemistry · 2026Article
- Mapping the avoid-ome: a systematic open-science approach to predictive ADMET.Nature communications · 2026Review
- Drug Safety Assessment Based on Target Affinity, Drug Exposure and Plasma Protein Binding: Drug-Induced Cardiotoxicity from a Translational Pharmacology Perspective.International journal of molecular sciences · 2026Article
- Discovery and Characterization of a Nonacidic Small-Molecule Inhibitor of the Sodium-Coupled Dicarboxylate Transporter NaCT.Journal of medicinal chemistry · 2026Article
- Optical control of the cardiac rhythm with photoswitchable NaNature communications · 2026Article
241 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In vitro pharmacological profiling is increasingly being used earlier in the drug discovery process to identify undesirable off-target activity profiles that could hinder or halt the development of candidate drugs or even lead to market withdrawal if discovered after a drug is approved. Here, for the first time, the rationale, strategies and methodologies for in vitro pharmacological profiling at four major pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Novartis and Pfizer) are presented and illustrated with examples of their impact on the drug discovery process. We hope that this will enable other companies and academic institutions to benefit from this knowledge and consider joining us in our collaborative knowledge sharing.
Indexed as
Identifiers
23197038What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.